[go: up one dir, main page]

MX2018014162A - Procesos para preparar oligomeros de morfolino fosforodiamidato. - Google Patents

Procesos para preparar oligomeros de morfolino fosforodiamidato.

Info

Publication number
MX2018014162A
MX2018014162A MX2018014162A MX2018014162A MX2018014162A MX 2018014162 A MX2018014162 A MX 2018014162A MX 2018014162 A MX2018014162 A MX 2018014162A MX 2018014162 A MX2018014162 A MX 2018014162A MX 2018014162 A MX2018014162 A MX 2018014162A
Authority
MX
Mexico
Prior art keywords
processes
morpholino oligomers
phosphorodiamidate morpholino
oligomer
preparing
Prior art date
Application number
MX2018014162A
Other languages
English (en)
Other versions
MX383656B (es
Inventor
Cai Bao
Martini Mitchell
Thomas Katie
Shimabuku Ross
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of MX2018014162A publication Critical patent/MX2018014162A/es
Publication of MX383656B publication Critical patent/MX383656B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/062—Organo-phosphoranes without P-C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se refiere a procesos para preparar un oligomero (por ejemplo, un oligomero de morfolino). Los procesos sinteticos descritos en la presente pueden ser ventajosos para el escalar la sintesis de oligomeros mientras se mantiene el rendimiento general y pureza de un oligomero sintetizado.
MX2018014162A 2016-05-24 2017-05-24 Procesos para preparar oligómeros de morfolino fosforodiamidato. MX383656B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662340953P 2016-05-24 2016-05-24
US201662357134P 2016-06-30 2016-06-30
PCT/US2017/034284 WO2017205513A1 (en) 2016-05-24 2017-05-24 Processes for preparing phosphorodiamidate morpholino oligomers

Publications (2)

Publication Number Publication Date
MX2018014162A true MX2018014162A (es) 2019-04-01
MX383656B MX383656B (es) 2025-03-14

Family

ID=59078166

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014162A MX383656B (es) 2016-05-24 2017-05-24 Procesos para preparar oligómeros de morfolino fosforodiamidato.

Country Status (28)

Country Link
US (3) US10961262B2 (es)
EP (2) EP4406600A3 (es)
JP (1) JP6987081B2 (es)
KR (1) KR102504759B1 (es)
CN (1) CN109311920B (es)
AU (1) AU2017271524B2 (es)
BR (1) BR112018074270B1 (es)
CA (1) CA3024182A1 (es)
CO (1) CO2018013827A2 (es)
DK (1) DK3464306T3 (es)
ES (1) ES2987586T3 (es)
FI (1) FI3464306T3 (es)
HR (1) HRP20240583T1 (es)
HU (1) HUE066393T2 (es)
IL (1) IL263033B2 (es)
LT (1) LT3464306T (es)
MA (2) MA45155B1 (es)
MD (1) MD3464306T2 (es)
MX (1) MX383656B (es)
PL (1) PL3464306T3 (es)
PT (1) PT3464306T (es)
RS (1) RS65504B1 (es)
SA (1) SA518400462B1 (es)
SG (1) SG11201809499UA (es)
SI (1) SI3464306T1 (es)
SM (1) SMT202400183T1 (es)
TW (1) TWI737736B (es)
WO (1) WO2017205513A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
RS65504B1 (sr) 2016-05-24 2024-06-28 Sarepta Therapeutics Inc Procesi za pripremu fosfordiamidat morfolino oligomera
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
AU2017270598B2 (en) * 2016-05-24 2022-12-01 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
HRP20241428T1 (hr) 2016-05-24 2025-01-03 Sarepta Therapeutics, Inc. Postupci za pripremu oligomera
AU2017270975B2 (en) 2016-05-24 2021-04-15 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MA45362A (fr) * 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
KR102523527B1 (ko) * 2016-06-30 2023-04-20 사렙타 쎄러퓨틱스 인코퍼레이티드 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법
US20200362339A1 (en) * 2017-09-25 2020-11-19 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US20210308273A1 (en) 2018-08-02 2021-10-07 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CN109704980B (zh) * 2019-02-16 2022-05-13 安徽大学 一种(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的制备方法
JPWO2021187392A1 (es) * 2020-03-16 2021-09-23
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
KR20240095330A (ko) * 2021-11-01 2024-06-25 다인 세라퓨틱스, 인크. 디스트로핀병증을 치료하기 위한 근육 표적화 복합체

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
DE3650349T2 (de) 1985-03-15 1995-12-14 Antivirals Inc Immunotestmittel für polynukleotid und verfahren.
CA1339987C (en) 1988-09-01 1998-08-04 Robert Bruce Merrifield Peptide synthesis method and solid support for use in the method
HUT76280A (en) 1993-12-29 1997-07-28 Fujisawa Pharmaceutical Co Pyrazolopyridine derivatives, pharmaceutical compositions containing them, process for proiducing them and their use
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
EP1282699B1 (en) 2000-05-04 2012-11-21 Sarepta Therapeutics, Inc. Splice-region antisense composition and method
US7060809B2 (en) 2001-09-04 2006-06-13 Exiqon A/S LNA compositions and uses thereof
US7569575B2 (en) 2002-05-08 2009-08-04 Santaris Pharma A/S Synthesis of locked nucleic acid derivatives
AU2003291682A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US7759513B2 (en) 2003-02-21 2010-07-20 Nigu Chemie Gmbh Photolabile protective groups for improved processes to prepare oligonucleotide arrays
EP4272748A3 (en) 2004-06-28 2024-03-27 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US9371348B2 (en) 2006-11-27 2016-06-21 The Trustees Of The University Of Pennsylvania Photocleavable oligonucleotide and uses thereof
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
CA2704261C (en) * 2007-11-15 2015-05-26 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US20120149756A1 (en) 2009-04-10 2012-06-14 Associatin Institut de Myologie Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
SMT201800579T1 (it) 2009-11-12 2019-01-11 Univ Western Australia Molecole antisenso e metodi per trattare patologie
WO2011150408A2 (en) * 2010-05-28 2011-12-01 Avi Biopharma, Inc. Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
TWI463423B (zh) * 2010-05-28 2014-12-01 Poynt Corp 用以針對基於三維形狀之廣告系統使用位置資訊的方法
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
DK2623507T3 (da) * 2010-09-30 2017-01-02 Nippon Shinyaku Co Ltd Morpholinonukleinsyrederivat
US9078911B2 (en) * 2011-02-08 2015-07-14 The Charlotte-Mecklenburg Hospital Authority Antisense oligonucleotides
US9920084B2 (en) 2011-08-23 2018-03-20 The Royal Institution For The Advancement Of Learning/Mcgill University Ionic tags for synthesis of oligoribonucleotides
ES2535654T3 (es) 2011-10-13 2015-05-13 Association Institut De Myologie ADN triciclo-fosforotioato
CN108864192A (zh) 2011-11-18 2018-11-23 萨勒普塔医疗公司 功能改性的寡核苷酸及其亚单元
US9944926B2 (en) 2011-11-30 2018-04-17 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
CN108486116A (zh) * 2011-12-28 2018-09-04 日本新药株式会社 反义核酸
EP3287531B1 (en) 2012-02-28 2019-06-19 Agilent Technologies, Inc. Method for attaching a counter sequence to a nucleic acid sample
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
CN105378081B (zh) * 2013-03-14 2019-06-14 萨勒普塔医疗公司 用于治疗肌营养不良的外显子跳跃组合物
EP2970964B8 (en) * 2013-03-14 2019-03-06 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
HK1220154A1 (zh) * 2013-03-15 2017-04-28 Sarepta Therapeutics, Inc. 改进的用於治疗肌营养不良的组合物
US8999152B2 (en) * 2013-03-15 2015-04-07 Uop Llc Process and apparatus for recovering and blending hydroprocessed hydrocarbons and composition
CN105228999B (zh) * 2013-05-24 2021-03-02 味之素株式会社 吗啉代寡核苷酸的制备方法
MA45362A (fr) * 2016-05-24 2019-04-10 Sarepta Therapeutics Inc Procédés de préparation d'oligomères morpholino de phosphorodiamidate
HRP20241428T1 (hr) * 2016-05-24 2025-01-03 Sarepta Therapeutics, Inc. Postupci za pripremu oligomera
RS65504B1 (sr) 2016-05-24 2024-06-28 Sarepta Therapeutics Inc Procesi za pripremu fosfordiamidat morfolino oligomera
AU2017270975B2 (en) 2016-05-24 2021-04-15 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
KR102552428B1 (ko) 2016-12-19 2023-07-06 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체

Also Published As

Publication number Publication date
BR112018074270A2 (pt) 2019-03-12
CO2018013827A2 (es) 2018-12-28
JP6987081B2 (ja) 2021-12-22
PT3464306T (pt) 2024-05-17
CN109311920A (zh) 2019-02-05
HUE066393T2 (hu) 2024-07-28
FI3464306T3 (fi) 2024-05-16
JP2019523754A (ja) 2019-08-29
EP4406600A3 (en) 2024-10-30
AU2017271524B2 (en) 2021-06-24
MA71469A (fr) 2025-04-30
KR102504759B1 (ko) 2023-02-28
DK3464306T3 (da) 2024-05-21
TWI737736B (zh) 2021-09-01
SA518400462B1 (ar) 2022-06-12
MD3464306T2 (ro) 2024-08-31
ES2987586T3 (es) 2024-11-15
IL263033B2 (en) 2023-02-01
IL263033B (en) 2022-10-01
TW201825506A (zh) 2018-07-16
US20190276480A1 (en) 2019-09-12
SMT202400183T1 (it) 2024-07-09
MX383656B (es) 2025-03-14
EP3464306B1 (en) 2024-03-27
IL263033A (en) 2018-12-31
RS65504B1 (sr) 2024-06-28
LT3464306T (lt) 2024-05-10
US20220340605A1 (en) 2022-10-27
CA3024182A1 (en) 2017-11-30
EP3464306A1 (en) 2019-04-10
US20250276988A1 (en) 2025-09-04
MA45155B1 (fr) 2024-06-28
EP4406600A2 (en) 2024-07-31
BR112018074270B1 (pt) 2021-02-02
PL3464306T3 (pl) 2024-07-22
US12258362B2 (en) 2025-03-25
AU2017271524A1 (en) 2018-11-15
SG11201809499UA (en) 2018-12-28
MA45155A (fr) 2019-04-10
HRP20240583T1 (hr) 2024-07-19
US10961262B2 (en) 2021-03-30
CN109311920B (zh) 2021-11-09
WO2017205513A1 (en) 2017-11-30
KR20190013844A (ko) 2019-02-11
SI3464306T1 (sl) 2024-08-30

Similar Documents

Publication Publication Date Title
CO2018013827A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
CO2018013834A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
CO2018013838A2 (es) Procesos para preparar oligómeros
CO2018013831A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
CO2019002975A2 (es) Compuestos de tetraciclina y métodos de uso de los mismos
AR132627A2 (es) Procesos para preparar compuestos intermediarios de utilidad para sintetizar compuestos de carbamoilpiridona policíclicos
SA518400463B1 (ar) عمليات لتحضير أوليجومرات فوسفوروداي أميدات مورفولينو
CL2019002297A1 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
MX386187B (es) Compuestos de benzo[b]tiofeno como agonistas de sting.
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
MX380263B (es) Procesos para producir brivaracetam.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
MX2019000664A (es) Preparacion de 14-metil-16-oxabiciclo[10.3.1]pentadecenos de 3-metil-1,5 ciclopentadecanediona.
AR116790A1 (es) PROCEDIMIENTO PARA LA PREPARACIÓN DE 3a-HIDROXI-5a-PREGNAN-20-ONA (BREXANOLONA)
DOP2016000211A (es) Pirazinas moduladoras de gpr6
MX2018014128A (es) 6.7.beta-epoxidos esteroideos como intermedios quimicos.
MX2022001608A (es) Sintesis de un inhibidor de calicreina plasmatica a escala de proceso.
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
BR112017018993A2 (pt) Processo para preparar 3-cloro-2- vinilfenilassulfonatos
MX2019011517A (es) Proceso para producir analogos de anillo de arilomicina.
CU20190035A7 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina
AR101951A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
CY1125227T1 (el) Μορφες δοσολογιας που περιλαμβανουν αναστολεα kαλλικρεϊνης πλασματος
EA201791098A1 (ru) Способ синтеза производных бензазепина